- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 - - Solid received a positive opinion from the European
CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units (“RSUs”) to one newly hired
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing
- Orphan drug designation from the European Commission underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 25th
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 - - Company
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-generation investigational gene therapy for
CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026 ; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized,